| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Lung Cancer Research Group, Institut National de la Santé et de la Recherche Médicale, La Tronche, and 2 Dépt de Médecine Aigue Specialisée Pneumologie, and 3 Laboratoire de Pathologie Cellulaire, and 4 Dépt de Chirurgie Cardiovasculaire Endocrinienne et Thoracique, Hôpital Albert Michallon, Grenoble, France.
CORRESPONDENCE: D. Moro-Sibilot, DMAS Pneumologie, Hôpital Albert Michallon, BP217 38043 Grenoble Cedex 9, France. Fax: 33 476765617. E-mail: DMoro.pneumo@chu-grenoble.fr
Keywords: Lung cancer, lung cancer treatment, prognostic factors, surgery, survival analysis
Received: December 20, 2004
Accepted May 30, 2005
Patients with nonsmall cell lung cancer (NSCLC) have been shown to have a higher prevalence of comorbidity associated with age and tobacco consumption. The objective of the present study was to determine the impact of comorbidity on survival after surgery of stage I NSCLC.
In total, 588 consecutive patients operated on for a pathological stage I NSCLC between January 1, 1979 and December 31, 2003 were studied. Comorbidities were analysed individually. Overall comorbidity was assessed using the Charlson index of comorbidity (CCI). Survival data were collected for each patient from the date of operation, with a median duration of follow-up of 104 months. Survival analyses and Cox proportional hazards model analyses were used.
The mean age of patients was 62.7 yrs, and 529 (89%) patients were male. The distribution of overall comorbidity severity was as follows. CCI grade 0: 47.1%; grade 1–2: 43.7%; grade 3–4: 8.3%; and grade
The 2, 3 and 5 yrs survival were 69, 62 and 50%, respectively. Multivariable analysis showed that T stage, age, a concomitant history of moderate-to-severe liver disease, a past history of cured cancer, cerebrovascular disease and CCI were independent predictors of survival (Hazard Ratio for CCI grade >2: 1.81; 95% confidence interval 1.25–2.63).
In conclusion, comorbidity has a significant impact on survival after surgical resection of patients with stage I nonsmall cell lung cancer. The use of a validated index of comorbidity in prognostic analyses of resected nonsmall cell lung cancer is recommended.
5: 0.8%.
This article has been cited by other articles:
|
|
 |
|
  F. Farjah, D. E. Wood, D. Yanez III, R. G. Symons, B. Krishnadasan, and D. R. Flum Temporal trends in the management of potentially resectable lung cancer. Ann. Thorac. Surg., June 1, 2008; 85(6): 1850 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Wang, Y.-S. Lin, C. Tzao, H.-C. Lee, M.-H. Huang, W.-H. Hsu, and H.-S. Hsu Comparison of Charlson comorbidity index and Kaplan Feinstein index in patients with stage I lung cancer after surgical resection Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 877 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-E. Strand, H. Rostad, R. A M Damhuis, and J. Norstein Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude Thorax, November 1, 2007; 62(11): 991 - 997. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
